We are very pleased to announce the publication of the first article describing our Quantum Blue® Infliximab trough level assay. The authors around Professor F. Magro claim that: “On the basis of this study, we may conclude that the point-of-care Quantum Blue is a reliable alternative to the time-consuming ELISAs, allowing the fast and accurate assessment of
- info@buhlmannlabs.ch
- +41 61 487 12 12
News
A new publication using BÜHLMANN Quantum Blue® fCAL is looking at the impact of using fecal Calprotectin in IBD management . Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211.PMID:27688663. “The FC test effected a change in management 51.3% of the time and
New BÜHLMANN fCAL® turbo publication Nilsen, T. et. al. A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers. J Clin Lab Anal. 2016 Sep 15. PMID:27629827 The publication describes the technical performance of the turbidimetric assay on the cobas c501 and the Mindray BS-380. Highlights from this Publication: Short assay time of 10 min with
Social Links